UBS Group
BEAM icon

UBS Group’s Beam Therapeutics BEAM Stock Holding History

UBS Group’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-49,600
Closed -$3.97M – 9382
2021
Q1 		$3.97M Buy
+49,600
New +$4.72M ﹤0.01% 2860

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

UBS Group's BEAM Position: Q2 2026 in Review

UBS Group reduced its Beam Therapeutics (BEAM) stake by 30% in Q2 2026, selling an estimated $7.59M and leaving 574,814 shares worth $19.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2696.

UBS Group first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. The position peaked at $45.1M in Q4 2024. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • UBS Group held 574,814 shares of Beam Therapeutics worth $19.7M as of Q2 2026.
  • UBS Group sold 251,247 Beam Therapeutics shares in Q2 2026, an estimated $7.59M.
  • Beam Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2696 holding.
  • UBS Group first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • UBS Group's Beam Therapeutics position peaked at $45.1M in Q4 2024.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.